176 related articles for article (PubMed ID: 20425063)
21. Understanding the type 2 diabetes mellitus and cardiovascular disease risk paradox.
Green JB
Postgrad Med; 2014 May; 126(3):190-204. PubMed ID: 24918803
[TBL] [Abstract][Full Text] [Related]
22. Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists.
Ji Q
Clin Ther; 2017 Jun; 39(6):1244-1264. PubMed ID: 28526416
[TBL] [Abstract][Full Text] [Related]
23. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials.
Kaul S
Diabetes Care; 2017 Jul; 40(7):821-831. PubMed ID: 28637887
[TBL] [Abstract][Full Text] [Related]
24. Glucagon-like peptide 1 receptor agonists and cardiovascular risk in type 2 diabetes: a clinical perspective.
Fisher M
Diabetes Obes Metab; 2015 Apr; 17(4):335-42. PubMed ID: 25155010
[TBL] [Abstract][Full Text] [Related]
25. Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis.
Han Y; Xie H; Liu Y; Gao P; Yang X; Shen Z
Cardiovasc Diabetol; 2019 Jul; 18(1):96. PubMed ID: 31362743
[TBL] [Abstract][Full Text] [Related]
26. Treating diabetes: cardiovascular benefits of antidiabetes drugs.
Harmel AP
Am J Manag Care; 2002 May; 8(8 Suppl):S219-28; quiz S229-32. PubMed ID: 12022237
[TBL] [Abstract][Full Text] [Related]
27. [Safety and tolerability of oral hypoglycemic therapies in type 2 diabetes mellitus patients at high cardiovascular risk].
Ambrosio G; De Ferrari GM; Federici M; Filardi PP
G Ital Cardiol (Rome); 2017 Jun; 18(6):485-495. PubMed ID: 28631762
[TBL] [Abstract][Full Text] [Related]
28. The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients.
Charbonnel B; Dormandy J; Erdmann E; Massi-Benedetti M; Skene A;
Diabetes Care; 2004 Jul; 27(7):1647-53. PubMed ID: 15220241
[TBL] [Abstract][Full Text] [Related]
29. The Role of Hypoglycemia in Cardiovascular Outcomes in Diabetes.
Paty BW
Can J Diabetes; 2015 Dec; 39 Suppl 5():S155-9. PubMed ID: 26654859
[TBL] [Abstract][Full Text] [Related]
30. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
[TBL] [Abstract][Full Text] [Related]
31. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus.
Hemmingsen B; Schroll JB; Lund SS; Wetterslev J; Gluud C; Vaag A; Sonne DP; Lundstrøm LH; Almdal T
Cochrane Database Syst Rev; 2013 Apr; (4):CD009008. PubMed ID: 23633364
[TBL] [Abstract][Full Text] [Related]
32. Antidiabetic Drugs as Antihypertensives: New Data on the Horizon.
Mamakou V; Eleftheriadou I; Katsiki N; Makrilakis K; Tsioufis K; Tentolouris N
Curr Vasc Pharmacol; 2017; 16(1):70-78. PubMed ID: 29032756
[TBL] [Abstract][Full Text] [Related]
33. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
Ou HT; Chang KC; Li CY; Wu JS
Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
[TBL] [Abstract][Full Text] [Related]
34. Mechanisms of Cardiovascular Injury in Type 2 Diabetes and Potential Effects of Dipeptidyl Peptidase-4 Inhibition.
Dokken B
J Cardiovasc Nurs; 2016; 31(3):274-83. PubMed ID: 25829138
[TBL] [Abstract][Full Text] [Related]
35. Cardiovascular safety of metformin and sulfonylureas in patients with different cardiac risk profiles.
Wurm R; Resl M; Neuhold S; Prager R; Brath H; Francesconi C; Vila G; Strunk G; Clodi M; Luger A; Pacher R; Hülsmann M
Heart; 2016 Oct; 102(19):1544-51. PubMed ID: 27226327
[TBL] [Abstract][Full Text] [Related]
36. [Cardiovascular Effects of Antidiabetic Therapies].
Laubner K; Seufert J
Dtsch Med Wochenschr; 2017 May; 142(10):737-745. PubMed ID: 28514822
[TBL] [Abstract][Full Text] [Related]
37. [Impact of antidiabetic therapy on the risk of cardiovascular diseases and their complications in patients with type 2 diabetes mellitus].
Ametov AS; P'ianykh OP; Chernikova NA
Ter Arkh; 2010; 82(8):71-5. PubMed ID: 20873250
[TBL] [Abstract][Full Text] [Related]
38. Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials.
Gebrie D; Getnet D; Manyazewal T
Sci Rep; 2021 Jan; 11(1):137. PubMed ID: 33420333
[TBL] [Abstract][Full Text] [Related]
39. Antidiabetic agents and cardiovascular outcomes in patients with heart diseases.
Cheng JWM; Badreldin HA; Patel DK; Bhatt SH
Curr Med Res Opin; 2017 Jun; 33(6):985-992. PubMed ID: 28097882
[TBL] [Abstract][Full Text] [Related]
40. Novel antidiabetic drugs and cardiovascular risk: Primum non nocere.
Bonadonna RC; Borghi C; Consoli A; Volpe M
Nutr Metab Cardiovasc Dis; 2016 Sep; 26(9):759-66. PubMed ID: 27373139
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]